Parsons Capital Management Inc. RI lowered its holdings in shares of MiMedx Group, Inc. (NASDAQ:MDXG – Free Report) by 4.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 217,146 shares of the company’s stock after selling 10,000 shares during the quarter. Parsons Capital Management Inc. RI owned approximately 0.15% of MiMedx Group worth $1,505,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of MDXG. Harbor Capital Advisors Inc. purchased a new position in shares of MiMedx Group in the second quarter valued at approximately $1,781,000. Caxton Associates LP purchased a new position in shares of MiMedx Group in the first quarter valued at approximately $1,018,000. Price T Rowe Associates Inc. MD increased its holdings in shares of MiMedx Group by 13.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 32,978 shares of the company’s stock valued at $254,000 after purchasing an additional 3,806 shares during the last quarter. Shell Asset Management Co. acquired a new stake in shares of MiMedx Group in the first quarter valued at approximately $113,000. Finally, Hillsdale Investment Management Inc. increased its holdings in shares of MiMedx Group by 8.6% in the first quarter. Hillsdale Investment Management Inc. now owns 486,500 shares of the company’s stock valued at $3,746,000 after purchasing an additional 38,600 shares during the last quarter. Hedge funds and other institutional investors own 79.15% of the company’s stock.
MiMedx Group Stock Performance
Shares of MDXG stock opened at $6.58 on Tuesday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.71 and a current ratio of 3.85. MiMedx Group, Inc. has a one year low of $5.57 and a one year high of $9.27. The company’s 50-day simple moving average is $6.89 and its 200-day simple moving average is $7.28. The stock has a market capitalization of $971.23 million, a price-to-earnings ratio of 14.89 and a beta of 1.98.
Wall Street Analyst Weigh In
Check Out Our Latest Analysis on MDXG
MiMedx Group Company Profile
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
Further Reading
- Five stocks we like better than MiMedx Group
- What Does Downgrade Mean in Investing?
- Momentum in Palo Alto Networks: Tech Stocks Still Going Strong
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Buffett’s Big Bet: Should You Follow Berkshire’s Move on OXY?
- Short Selling: How to Short a Stock
- GeoVax Labs: Is This Micro-Cap Biotech Stock a Boom or a Bust?
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.